Epigenomic Market value is projected to reach US$ 44.56 Bn at the end of the forecast period and it is expected to grow at the CAGR of 22.04%. The report includes the analysis of the impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lockdown was implemented differently in different regions and countries, impact of the same is also different by regions and segments. The report has covered the current short-term and long-term impact on the market, same will help decision-makers to prepare the outline for short-term and long-term strategies for companies by region.To know about the Research Methodology:-Request Free Sample Report
Dynamics:
Growing applications in personalized medicine & targeted therapy in oncology and the use of epigenetics in non-oncology applications is a growth opportunity for the epigenetics market. Increase in the prevalence of cancer & other chronic diseases, a rise in the geriatric population, and a decrease in the DNA sequencing costs & time is driving the growth of the market. Government funding for research & development, need for better cancer therapies, development in personalized medicine, and the increasing importance of epigenetic technology such factors are drive the Global Epigenomic Market during forecast period. The high cost of instruments is limiting the growth of the market. Some challenges of the market are concerns regarding the quality of antibodies, and a lack of trained professionals. On the basis of Product, the Global Epigenomic Market is segmented into Enzymes, Instruments and Consumables, Kits, Reagents and Bioinformatics Tools. In terms Application, the Global Epigenomic Market is segmented into Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases and Other application.Segment Analysis:
Furthermore, the reagents segment is sub-segmented into antibodies, buffers, histones, and magnetic beads. Reagents are used in the analysis of epigenetic changes and it is contributed the xx % shares to the epigenetics market, because of the sales volume of reagents is high in comparison to other equipment. The sales volume of reagents is high due to their increased affordability & ease of storage in less space. Rise in the number of collaborations between the large pharmaceutical companies to get into innovation & produce technologically advanced and effective products & service in North-America is leading the global epigenomic market. An Asia-pacific epigenomic market is estimated to grow rapidly, owing to the high incidence of cancer, a large occurrence of target diseases, the rise in healthcare expenditure, the increase in investments & funds, and various emerging applications.Global Epigenomic Market Regional Insights:
The objective of the report is to present comprehensive analysis of Global Epigenomic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Epigenomic Market dynamics, structure by analyzing the market segments, and project the Global Epigenomic Market size. Clear representation of competitive analysis of key players by Global Epigenomic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Epigenomic Market make the report investor’s guide.Global Epigenomic Market, Key Highlights:
Global Epigenomic Market analysis and forecast, in terms of value. Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Epigenomic Market Global Epigenomic Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. The Global Epigenomic Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. Global Epigenomic Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Epigenomic Market are also profiled.Global Epigenomic Market Scope: Inquire before buying
Global Epigenomic Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 11.05 Bn. Forecast Period 2022 to 2029 CAGR: 22.04% Market Size in 2029: US $ 44.56 Bn. Segments Covered: by Product Enzymes Instruments and Consumables Kits Reagents Bioinformatics Tools by Application Oncology Metabolic Diseases Developmental Biology Immunology Cardiovascular Diseases Other application by Technology DNA Methylation Histone Modifications Other Technologies by End-User Academic & Research Institutes Pharmaceutical & Biotechnology Companies Contract Research Organizations Global Epigenomic Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Epigenomic Market, Key Players
1. Abbott Laboratories 2. Affymetrix 3. Agilent Technologies 4. Astellas Pharmaceuticals 5. Bayer Ag 6. Bio Vision 7. Celgene Corp. 8. Epigenomics Ag 9. Epigentek 10.Glaxosmithkline 11.Illumina Inc. 12.Johnson & Johnson 13.Laboratory Corp. Of America Holdings 14.Merck Sharp & Dohme 15.Naturewise Biotech & Medicals Corp. 16.Novartis Pharma Ag 17.Orchid Chemicals & Pharmaceuticals Limited 18.Tbg Diagnostics Limited 19.Rubicon Genomics 20.Roche Holding Ag 21.Abcam plc 22.Thermo Fisher Scientific Inc. 23.Zymo Research Corporation 24.Eisai Frequently Asked Questions: 1. Which region has the largest share in Global Epigenomic Market? Ans: Asia Pacific region held the highest share in 2022. 2. What is the growth rate of Global Epigenomic Market? Ans: The Global Epigenomic Market is growing at a CAGR of 22.04% during forecasting period 2023-2029. 3. What is scope of the Global Epigenomic market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Epigenomic market? Ans: The important key players in the Global Epigenomic Market are – Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, Bayer Ag, Bio Vision, Celgene Corp., Epigenomics Ag, Epigentek, Glaxosmithkline, Illumina Inc., Johnson & Johnson, Laboratory Corp. Of America Holdings, Merck Sharp & Dohme, Naturewise Biotech & Medicals Corp., Novartis Pharma Ag, Orchid Chemicals & Pharmaceuticals Limited, Tbg Diagnostics Limited, Rubicon Genomics, Roche Holding Ag, Abcam plc, Thermo Fisher Scientific Inc., Zymo Research Corporation, and Eisai 5. What is the study period of this market? Ans: The Global Epigenomic Market is studied from 2022 to 2029.
Global Epigenomic Market
1. Preface 1.1. Research Objectives 1.2. Report Scope and Market Segmentation 2. Assumptions and Research Methodology 2.1. Abbreviations 3. Executive Summary 3.1. Global Epigenomic Market Size, by Market Value (US$ Bn) and Market 4. Market Overview 4.1. Introduction 4.2. Market Dynamics 4.3. Drivers and Restraints Snapshot Analysis 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.3.4. Porter’s Analysis 4.3.5. Value Chain Analysis 4.3.6. SWOT Analysis 4.3.7. Key Trends in Global Epigenomic Market 5. Global Epigenomic Market Analysis and Forecast 5.1. Global Epigenomic Market Size& Y-o-Y Growth Analysis 5.1.1. North America 5.1.2. Europe 5.1.3. Asia Pacific 5.1.4. Middle East & Africa 5.1.5. South America 6. Global Epigenomic Market Analysis and Forecast, By Product 6.1. Introduction and Definition 6.2. Global Epigenomic Market Value Share Analysis, By Product 6.3. Global Epigenomic Market Size (US$ Bn) Forecast, By Product 6.4. Global Epigenomic Market Analysis, By Product 6.5. Global Epigenomic Market Attractiveness Analysis, By Product 6.6. Key Trends 6.6.1. Key Developments 7. Global Epigenomic Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Global Epigenomic Market Value Share Analysis, By Application 7.3. Global Epigenomic Market Size (US$ Bn) Forecast, By Application 7.4. Global Epigenomic Market Analysis, By Application 7.5. Global Epigenomic Market Attractiveness Analysis, By Application 7.6. Key Trends 7.6.1. Key Developments 8. Global Epigenomic Market Analysis and Forecast, By Technology 8.1. Introduction and Definition 8.2. Global Epigenomic Market Value Share Analysis, By Technology 8.3. Global Epigenomic Market Size (US$ Bn) Forecast, By Technology 8.4. Global Epigenomic Market Analysis, By Technology 8.5. Global Epigenomic Market Attractiveness Analysis, By Technology 8.6. Key Trends 8.6.1. Key Developments 9. Global Epigenomic Market Analysis and Forecast, By End-User 9.1. Introduction and Definition 9.2. Global Epigenomic Market Value Share Analysis, By End-User 9.3. Global Epigenomic Market Size (US$ Bn) Forecast, By End-User 9.4. Global Epigenomic Market Analysis, By End-User 9.5. Global Epigenomic Market Attractiveness Analysis, By End-User 9.6. Key Trends 9.6.1. Key Developments 10. Global Epigenomic Market Analysis, by Region 10.1. Global Epigenomic Market Value Share Analysis, by Region 10.2. Global Epigenomic Market Size (US$ Bn) Forecast, by Region 10.3. Global Epigenomic Market Attractiveness Analysis, by Region 10.4. Key Trends 10.4.1. Key Developments 11. North America Epigenomic Market Analysis 11.1. Key Findings 11.2. North America Epigenomic Market Overview 11.3. North America Epigenomic Market Value Share Analysis, By Product 11.4. North America Epigenomic Market Forecast, By Product 11.4.1. Enzymes 11.4.2. Instruments and Consumables 11.4.3. Kits 11.4.4. Reagents 11.4.5. Bioinformatics Tools 11.5. North America Epigenomic Market Value Share Analysis, By Application 11.6. North America Epigenomic Market Forecast, By Application 11.6.1. Oncology 11.6.2. Metabolic Diseases 11.6.3. Developmental Biology 11.6.4. Immunology 11.6.5. Cardiovascular Diseases 11.6.6. Other application 11.7. North America Epigenomic Market Value Share Analysis, By Technology 11.8. North America Epigenomic Market Forecast, By Technology 11.8.1. DNA Methylation 11.8.2. Histone Modifications 11.8.3. Other Technologies 11.9. North America Epigenomic Market Value Share Analysis, By End-User 11.10. North America Epigenomic Market Forecast, By End-User 11.10.1. Academic & Research Institutes 11.10.2. Pharmaceutical & Biotechnology Companies 11.10.3. Contract Research Organizations 11.11. North America Epigenomic Market Value Share Analysis, by Country 11.12. North America Epigenomic Market Forecast, by Country 11.12.1. U.S. 11.12.2. Canada 11.13. North America Epigenomic Market Analysis, by Country 11.14. U.S. Epigenomic Market Forecast, By Product 11.14.1. Enzymes 11.14.2. Instruments and Consumables 11.14.3. Kits 11.14.4. Reagents 11.14.5. Bioinformatics Tools 11.15. U.S. Epigenomic Market Forecast, By Application 11.15.1. Oncology 11.15.2. Metabolic Diseases 11.15.3. Developmental Biology 11.15.4. Immunology 11.15.5. Cardiovascular Diseases 11.15.6. Other application 11.16. U.S. Epigenomic Market Forecast, By Technology 11.16.1. DNA Methylation 11.16.2. Histone Modifications 11.16.3. Other Technologies 11.17. U.S. Epigenomic Market Forecast, By End-User 11.17.1. Academic & Research Institutes 11.17.2. Pharmaceutical & Biotechnology Companies 11.17.3. Contract Research Organizations 11.18. Canada Epigenomic Market Forecast, By Product 11.18.1. Enzymes 11.18.2. Instruments and Consumables 11.18.3. Kits 11.18.4. Reagents 11.18.5. Bioinformatics Tools 11.19. Canada Epigenomic Market Forecast, By Application 11.19.1. Oncology 11.19.2. Metabolic Diseases 11.19.3. Developmental Biology 11.19.4. Immunology 11.19.5. Cardiovascular Diseases 11.19.6. Other application 11.20. Canada Epigenomic Market Forecast, By Technology 11.20.1. DNA Methylation 11.20.2. Histone Modifications 11.20.3. Other Technologies 11.21. Canada Epigenomic Market Forecast, By End-User 11.21.1. Academic & Research Institutes 11.21.2. Pharmaceutical & Biotechnology Companies 11.21.3. Contract Research Organizations 11.22. North America Epigenomic Market Attractiveness Analysis 11.22.1. By Product 11.22.2. By Application 11.22.3. By Technology 11.22.4. By End-User 11.23. PEST Analysis 11.24. Key Trends 11.24.1. Key Developments 12. Europe Epigenomic Market Analysis 12.1. Key Findings 12.2. Europe Epigenomic Market Overview 12.3. Europe Epigenomic Market Value Share Analysis, By Product 12.4. Europe Epigenomic Market Forecast, By Product 12.4.1. Enzymes 12.4.2. Instruments and Consumables 12.4.3. Kits 12.4.4. Reagents 12.4.5. Bioinformatics Tools 12.5. Europe Epigenomic Market Value Share Analysis, By Application 12.6. Europe Epigenomic Market Forecast, By Application 12.6.1. Oncology 12.6.2. Metabolic Diseases 12.6.3. Developmental Biology 12.6.4. Immunology 12.6.5. Cardiovascular Diseases 12.6.6. Other application 12.7. Europe Epigenomic Market Value Share Analysis, By Technology 12.8. Europe Epigenomic Market Forecast, By Technology 12.8.1. DNA Methylation 12.8.2. Histone Modifications 12.8.3. Other Technologies 12.9. Europe Epigenomic Market Value Share Analysis, By End-User 12.10. Europe Epigenomic Market Forecast, By End-User 12.10.1. Academic & Research Institutes 12.10.2. Pharmaceutical & Biotechnology Companies 12.10.3. Contract Research Organizations 12.11. Europe Epigenomic Market Value Share Analysis, by Country 12.12. Europe Epigenomic Market Forecast, by Country 12.12.1. Germany 12.12.2. U.K. 12.12.3. France 12.12.4. Italy 12.12.5. Spain 12.12.6. Rest of Europe 12.13. Europe Epigenomic Market Analysis, by Country/ Sub-region 12.14. Germany Epigenomic Market Forecast, By Product 12.14.1. Enzymes 12.14.2. Instruments and Consumables 12.14.3. Kits 12.14.4. Reagents 12.14.5. Bioinformatics Tools 12.15. Germany Epigenomic Market Forecast, By Application 12.15.1. Oncology 12.15.2. Metabolic Diseases 12.15.3. Developmental Biology 12.15.4. Immunology 12.15.5. Cardiovascular Diseases 12.15.6. Other application 12.16. Germany Epigenomic Market Forecast, By Technology 12.16.1. DNA Methylation 12.16.2. Histone Modifications 12.16.3. Other Technologies 12.17. Germany Epigenomic Market Forecast, By End-User 12.17.1. Academic & Research Institutes 12.17.2. Pharmaceutical & Biotechnology Companies 12.17.3. Contract Research Organizations 12.18. U.K. Epigenomic Market Forecast, By Product 12.18.1. Enzymes 12.18.2. Instruments and Consumables 12.18.3. Kits 12.18.4. Reagents 12.18.5. Bioinformatics Tools 12.19. U.K. Epigenomic Market Forecast, By Application 12.19.1. Oncology 12.19.2. Metabolic Diseases 12.19.3. Developmental Biology 12.19.4. Immunology 12.19.5. Cardiovascular Diseases 12.19.6. Other application 12.20. U.K. Epigenomic Market Forecast, By Technology 12.20.1. DNA Methylation 12.20.2. Histone Modifications 12.20.3. Other Technologies 12.21. U.K. Epigenomic Market Forecast, By End-User 12.21.1. Academic & Research Institutes 12.21.2. Pharmaceutical & Biotechnology Companies 12.21.3. Contract Research Organizations 12.22. France Epigenomic Market Forecast, By Product 12.22.1. Enzymes 12.22.2. Instruments and Consumables 12.22.3. Kits 12.22.4. Reagents 12.22.5. Bioinformatics Tools 12.23. France Epigenomic Market Forecast, By Application 12.23.1. Oncology 12.23.2. Metabolic Diseases 12.23.3. Developmental Biology 12.23.4. Immunology 12.23.5. Cardiovascular Diseases 12.23.6. Other application 12.24. France Epigenomic Market Forecast, By Technology 12.24.1. DNA Methylation 12.24.2. Histone Modifications 12.24.3. Other Technologies 12.25. France Epigenomic Market Forecast, By End-User 12.25.1. Academic & Research Institutes 12.25.2. Pharmaceutical & Biotechnology Companies 12.25.3. Contract Research Organizations 12.26. Italy Epigenomic Market Forecast, By Product 12.26.1. Enzymes 12.26.2. Instruments and Consumables 12.26.3. Kits 12.26.4. Reagents 12.26.5. Bioinformatics Tools 12.27. Italy Epigenomic Market Forecast, By Application 12.27.1. Oncology 12.27.2. Metabolic Diseases 12.27.3. Developmental Biology 12.27.4. Immunology 12.27.5. Cardiovascular Diseases 12.27.6. Other application 12.28. Italy Epigenomic Market Forecast, By Technology 12.28.1. DNA Methylation 12.28.2. Histone Modifications 12.28.3. Other Technologies 12.29. Italy Epigenomic Market Forecast, By End-User 12.29.1. Academic & Research Institutes 12.29.2. Pharmaceutical & Biotechnology Companies 12.29.3. Contract Research Organizations 12.30. Spain Epigenomic Market Forecast, By Product 12.30.1. Enzymes 12.30.2. Instruments and Consumables 12.30.3. Kits 12.30.4. Reagents 12.30.5. Bioinformatics Tools 12.31. Spain Epigenomic Market Forecast, By Application 12.31.1. Oncology 12.31.2. Metabolic Diseases 12.31.3. Developmental Biology 12.31.4. Immunology 12.31.5. Cardiovascular Diseases 12.31.6. Other application 12.32. Spain Epigenomic Market Forecast, By Technology 12.32.1. DNA Methylation 12.32.2. Histone Modifications 12.32.3. Other Technologies 12.33. Spain Epigenomic Market Forecast, By End-User 12.33.1. Academic & Research Institutes 12.33.2. Pharmaceutical & Biotechnology Companies 12.33.3. Contract Research Organizations 12.34. Rest of Europe Epigenomic Market Forecast, By Product 12.34.1. Enzymes 12.34.2. Instruments and Consumables 12.34.3. Kits 12.34.4. Reagents 12.34.5. Bioinformatics Tools 12.35. Rest of Europe Epigenomic Market Forecast, By Application 12.35.1. Oncology 12.35.2. Metabolic Diseases 12.35.3. Developmental Biology 12.35.4. Immunology 12.35.5. Cardiovascular Diseases 12.35.6. Other application 12.36. Rest of Europe Epigenomic Market Forecast, By Technology 12.36.1. DNA Methylation 12.36.2. Histone Modifications 12.36.3. Other Technologies 12.37. Rest Of Europe Epigenomic Market Forecast, By End-User 12.37.1. Academic & Research Institutes 12.37.2. Pharmaceutical & Biotechnology Companies 12.37.3. Contract Research Organizations 12.38. Europe Epigenomic Market Attractiveness Analysis 12.38.1. By Product 12.38.2. By Application 12.38.3. By Technology 12.38.4. By End-User 12.39. PEST Analysis 12.40. Key Trends 12.40.1. Key Developments 13. Asia Pacific Epigenomic Market Analysis 13.1. Key Findings 13.2. Asia Pacific Epigenomic Market Overview 13.3. Asia Pacific Epigenomic Market Value Share Analysis, By Product 13.4. Asia Pacific Epigenomic Market Forecast, By Product 13.4.1. Enzymes 13.4.2. Instruments and Consumables 13.4.3. Kits 13.4.4. Reagents 13.4.5. Bioinformatics Tools 13.5. Asia Pacific Epigenomic Market Value Share Analysis, By Application 13.6. Asia Pacific Epigenomic Market Forecast, By Application 13.6.1. Oncology 13.6.2. Metabolic Diseases 13.6.3. Developmental Biology 13.6.4. Immunology 13.6.5. Cardiovascular Diseases 13.6.6. Other application 13.7. Asia Pacific Epigenomic Market Value Share Analysis, By Technology 13.8. Asia Pacific Epigenomic Market Forecast, By Technology 13.8.1. DNA Methylation 13.8.2. Histone Modifications 13.8.3. Other Technologies 13.9. Asia Pacific Epigenomic Market Value Share Analysis, By End-User 13.10. Asia Pacific Epigenomic Market Forecast, By End-User 13.10.1. Academic & Research Institutes 13.10.2. Pharmaceutical & Biotechnology Companies 13.10.3. Contract Research Organizations 13.11. Asia Pacific Epigenomic Market Value Share Analysis, by Country 13.12. Asia Pacific Epigenomic Market Forecast, by Country 13.12.1. China 13.12.2. India 13.12.3. Japan 13.12.4. ASEAN 13.12.5. Rest of Asia Pacific 13.13. Asia Pacific Epigenomic Market Analysis, by Country/ Sub-region 13.14. China Epigenomic Market Forecast, By Product 13.14.1. Enzymes 13.14.2. Instruments and Consumables 13.14.3. Kits 13.14.4. Reagents 13.14.5. Bioinformatics Tools 13.15. China Epigenomic Market Forecast, By Application 13.15.1. Oncology 13.15.2. Metabolic Diseases 13.15.3. Developmental Biology 13.15.4. Immunology 13.15.5. Cardiovascular Diseases 13.15.6. Other application 13.16. China Epigenomic Market Forecast, By Technology 13.16.1. DNA Methylation 13.16.2. Histone Modifications 13.16.3. Other Technologies 13.17. China Epigenomic Market Forecast, By End-User 13.17.1. Academic & Research Institutes 13.17.2. Pharmaceutical & Biotechnology Companies 13.17.3. Contract Research Organizations 13.18. India Epigenomic Market Forecast, By Product 13.18.1. Enzymes 13.18.2. Instruments and Consumables 13.18.3. Kits 13.18.4. Reagents 13.18.5. Bioinformatics Tools 13.19. India Epigenomic Market Forecast, By Application 13.19.1. Oncology 13.19.2. Metabolic Diseases 13.19.3. Developmental Biology 13.19.4. Immunology 13.19.5. Cardiovascular Diseases 13.19.6. Other application 13.20. India Epigenomic Market Forecast, By Technology 13.20.1. DNA Methylation 13.20.2. Histone Modifications 13.20.3. Other Technologies 13.21. India Epigenomic Market Forecast, By End-User 13.21.1. Academic & Research Institutes 13.21.2. Pharmaceutical & Biotechnology Companies 13.21.3. Contract Research Organizations 13.22. Japan Epigenomic Market Forecast, By Product 13.22.1. Enzymes 13.22.2. Instruments and Consumables 13.22.3. Kits 13.22.4. Reagents 13.22.5. Bioinformatics Tools 13.23. Japan Epigenomic Market Forecast, By Application 13.23.1. Oncology 13.23.2. Metabolic Diseases 13.23.3. Developmental Biology 13.23.4. Immunology 13.23.5. Cardiovascular Diseases 13.23.6. Other application 13.24. Japan Epigenomic Market Forecast, By Technology 13.24.1. DNA Methylation 13.24.2. Histone Modifications 13.24.3. Other Technologies 13.25. Japan Epigenomic Market Forecast, By End-User 13.25.1. Academic & Research Institutes 13.25.2. Pharmaceutical & Biotechnology Companies 13.25.3. Contract Research Organizations 13.26. ASEAN Epigenomic Market Forecast, By Product 13.26.1. Enzymes 13.26.2. Instruments and Consumables 13.26.3. Kits 13.26.4. Reagents 13.26.5. Bioinformatics Tools 13.27. ASEAN Epigenomic Market Forecast, By Application 13.27.1. Oncology 13.27.2. Metabolic Diseases 13.27.3. Developmental Biology 13.27.4. Immunology 13.27.5. Cardiovascular Diseases 13.27.6. Other application 13.28. ASEAN Epigenomic Market Forecast, By Technology 13.28.1. DNA Methylation 13.28.2. Histone Modifications 13.28.3. Other Technologies 13.29. ASEAN Epigenomic Market Forecast, By End-User 13.29.1. Academic & Research Institutes 13.29.2. Pharmaceutical & Biotechnology Companies 13.29.3. Contract Research Organizations 13.30. Rest of Asia Pacific Epigenomic Market Forecast, By Product 13.30.1. Enzymes 13.30.2. Instruments and Consumables 13.30.3. Kits 13.30.4. Reagents 13.30.5. Bioinformatics Tools 13.31. Rest of Asia Pacific Epigenomic Market Forecast, By Application 13.31.1. Oncology 13.31.2. Metabolic Diseases 13.31.3. Developmental Biology 13.31.4. Immunology 13.31.5. Cardiovascular Diseases 13.31.6. Other application 13.32. Rest of Asia Pacific Epigenomic Market Forecast, By Technology 13.32.1. DNA Methylation 13.32.2. Histone Modifications 13.32.3. Other Technologies 13.33. Rest of Asia Pacific Epigenomic Market Forecast, By End-User 13.33.1. Academic & Research Institutes 13.33.2. Pharmaceutical & Biotechnology Companies 13.33.3. Contract Research Organizations 13.34. Asia Pacific Epigenomic Market Attractiveness Analysis 13.34.1. By Product 13.34.2. By Application 13.34.3. By Technology 13.34.4. By End-User 13.35. PEST Analysis 13.36. Key Trends 13.36.1. Key Developments 14. Middle East & Africa Epigenomic Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Epigenomic Market Overview 14.3. Middle East & Africa Epigenomic Market Value Share Analysis, By Product 14.4. Middle East & Africa Epigenomic Market Forecast, By Product 14.4.1. Enzymes 14.4.2. Instruments and Consumables 14.4.3. Kits 14.4.4. Reagents 14.4.5. Bioinformatics Tools 14.5. Middle East & Africa Epigenomic Market Value Share Analysis, By Application 14.6. Middle East & Africa Epigenomic Market Forecast, By Application 14.6.1. Oncology 14.6.2. Metabolic Diseases 14.6.3. Developmental Biology 14.6.4. Immunology 14.6.5. Cardiovascular Diseases 14.6.6. Other application 14.7. Middle East & Africa Epigenomic Market Value Share Analysis, By Technology 14.8. Middle East & Africa Epigenomic Market Forecast, By Technology 14.8.1. DNA Methylation 14.8.2. Histone Modifications 14.8.3. Other Technologies 14.9. Middle East & Africa Epigenomic Market Value Share Analysis, By End-User 14.10. Middle East & Africa Epigenomic Market Forecast, By End-User 14.10.1. Academic & Research Institutes 14.10.2. Pharmaceutical & Biotechnology Companies 14.10.3. Contract Research Organizations 14.11. Middle East & Africa Epigenomic Market Value Share Analysis, by Country 14.12. Middle East & Africa Epigenomic Market Forecast, by Country 14.12.1. GCC 14.12.2. South Africa 14.12.3. Rest of Middle East & Africa 14.13. Middle East & Africa Epigenomic Market Analysis, by Country/ Sub-region 14.14. GCC Epigenomic Market Forecast, By Product 14.14.1. Enzymes 14.14.2. Instruments and Consumables 14.14.3. Kits 14.14.4. Reagents 14.14.5. Bioinformatics Tools 14.15. GCC Epigenomic Market Forecast, By Application 14.15.1. Oncology 14.15.2. Metabolic Diseases 14.15.3. Developmental Biology 14.15.4. Immunology 14.15.5. Cardiovascular Diseases 14.15.6. Other application 14.16. GCC Epigenomic Market Forecast, By Technology 14.16.1. DNA Methylation 14.16.2. Histone Modifications 14.16.3. Other Technologies 14.17. GCC Epigenomic Market Forecast, By End-User 14.18. Academic & Research Institutes 14.19. Pharmaceutical & Biotechnology Companies 14.20. Contract Research Organizations 14.21. Others South Africa Epigenomic Market Forecast, By Product 14.21.1. Enzymes 14.21.2. Instruments and Consumables 14.21.3. Kits 14.21.4. Reagents 14.21.5. Bioinformatics Tools 14.22. South Africa Epigenomic Market Forecast, By Application 14.22.1. Oncology 14.22.2. Metabolic Diseases 14.22.3. Developmental Biology 14.22.4. Immunology 14.22.5. Cardiovascular Diseases 14.22.6. Other application 14.23. South Africa Epigenomic Market Forecast, By Technology 14.23.1. DNA Methylation 14.23.2. Histone Modifications 14.23.3. Other Technologies 14.24. South Africa Epigenomic Market Forecast, By End-User 14.24.1. Academic & Research Institutes 14.24.2. Pharmaceutical & Biotechnology Companies 14.24.3. Contract Research Organizations 14.25. Rest of Middle East & Africa Epigenomic Market Forecast, By Product 14.25.1. Enzymes 14.25.2. Instruments and Consumables 14.25.3. Kits 14.25.4. Reagents 14.25.5. Bioinformatics Tools 14.26. Rest of Middle East & Africa Epigenomic Market Forecast, By Application 14.26.1. Oncology 14.26.2. Metabolic Diseases 14.26.3. Developmental Biology 14.26.4. Immunology 14.26.5. Cardiovascular Diseases 14.26.6. Other application 14.27. Rest of Middle East & Africa Epigenomic Market Forecast, By Technology 14.27.1. DNA Methylation 14.27.2. Histone Modifications 14.27.3. Other Technologies 14.28. Rest of Middle East & Africa Epigenomic Market Forecast, By End-User 14.28.1. Academic & Research Institutes 14.28.2. Pharmaceutical & Biotechnology Companies 14.28.3. Contract Research Organizations 14.29. Middle East & Africa Epigenomic Market Attractiveness Analysis 14.29.1. By Product 14.29.2. By Application 14.29.3. By Technology 14.29.4. By End-User 14.30. PEST Analysis 14.31. Key Trends 14.31.1. Key Developments 15. South America Epigenomic Market Analysis 15.1. Key Findings 15.2. South America Epigenomic Market Overview 15.3. South America Epigenomic Market Value Share Analysis, By Product 15.4. South America Epigenomic Market Forecast, By Product 15.4.1. Enzymes 15.4.2. Instruments and Consumables 15.4.3. Kits 15.4.4. Reagents 15.4.5. Bioinformatics Tools 15.5. South America Epigenomic Market Value Share Analysis, By Application 15.6. South America Epigenomic Market Forecast, By Application 15.6.1. Oncology 15.6.2. Metabolic Diseases 15.6.3. Developmental Biology 15.6.4. Immunology 15.6.5. Cardiovascular Diseases 15.6.6. Other application 15.7. South America Epigenomic Market Value Share Analysis, By Technology 15.8. South America Epigenomic Market Forecast, By Technology 15.8.1. DNA Methylation 15.8.2. Histone Modifications 15.8.3. Other Technologies 15.9. South America Epigenomic Market Value Share Analysis, By End-User 15.10. South America Epigenomic Market Forecast, By End-User 15.10.1. Academic & Research Institutes 15.10.2. Pharmaceutical & Biotechnology Companies 15.10.3. Contract Research Organizations 15.11. South America Epigenomic Market Value Share Analysis, by Country 15.12. South America Epigenomic Market Forecast, by Country 15.12.1. Brazil 15.12.2. Mexico 15.12.3. Rest of South America 15.13. South America Epigenomic Market Analysis, by Country/ Sub-region 15.14. Brazil Epigenomic Market Forecast, By Product 15.14.1. Enzymes 15.14.2. Instruments and Consumables 15.14.3. Kits 15.14.4. Reagents 15.14.5. Bioinformatics Tools 15.15. Brazil Epigenomic Market Forecast, By Application 15.15.1. Oncology 15.15.2. Metabolic Diseases 15.15.3. Developmental Biology 15.15.4. Immunology 15.15.5. Cardiovascular Diseases 15.15.6. Other application 15.16. Brazil Epigenomic Market Forecast, By Technology 15.16.1. DNA Methylation 15.16.2. Histone Modifications 15.16.3. Other Technologies 15.17. Brazil Epigenomic Market Forecast, By End-User 15.17.1. Academic & Research Institutes 15.17.2. Pharmaceutical & Biotechnology Companies 15.17.3. Contract Research Organizations 15.18. Mexico Epigenomic Market Forecast, By Product 15.18.1. Enzymes 15.18.2. Instruments and Consumables 15.18.3. Kits 15.18.4. Reagents 15.18.5. Bioinformatics Tools 15.19. Mexico Epigenomic Market Forecast, By Application 15.19.1. Oncology 15.19.2. Metabolic Diseases 15.19.3. Developmental Biology 15.19.4. Immunology 15.19.5. Cardiovascular Diseases 15.19.6. Other application 15.20. Mexico Epigenomic Market Forecast, By Technology 15.20.1. DNA Methylation 15.20.2. Histone Modifications 15.20.3. Other Technologies 15.21. Mexico Epigenomic Market Forecast, By End-User 15.21.1. Academic & Research Institutes 15.21.2. Pharmaceutical & Biotechnology Companies 15.21.3. Contract Research Organizations 15.22. Rest of South America Epigenomic Market Forecast, By Product 15.22.1. Enzymes 15.22.2. Instruments and Consumables 15.22.3. Kits 15.22.4. Reagents 15.22.5. Bioinformatics Tools 15.23. Rest of South America Epigenomic Market Forecast, By Application 15.23.1. Oncology 15.23.2. Metabolic Diseases 15.23.3. Developmental Biology 15.23.4. Immunology 15.23.5. Cardiovascular Diseases 15.23.6. Other application 15.24. Rest of South America Epigenomic Market Forecast, By Technology 15.24.1. DNA Methylation 15.24.2. Histone Modifications 15.24.3. Other Technologies 15.25. Rest of South America Epigenomic Market Forecast, By End-User 15.25.1. Academic & Research Institutes 15.25.2. Pharmaceutical & Biotechnology Companies 15.25.3. Contract Research Organizations 15.26. South America Epigenomic Market Attractiveness Analysis 15.26.1. By Product 15.26.2. By Application 15.26.3. By Technology 15.26.4. By End-User 15.27. PEST Analysis 15.28. Key Trends 15.28.1. Key Developments 16. Company Landscape 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.3. Competitive Benchmarking of Company and Services 16.4. Company Profiles: Key Players 16.4.1. Roche Holding Ag 16.4.1.1. Company Overview 16.4.1.2. Financial Overview 16.4.1.3. Business Strategy 16.4.1.4. Recent Developments 16.4.1.5. Development Footprint 16.4.2. Abbott Laboratories 16.4.3. Affymetrix 16.4.4. Agilent Technologies 16.4.5. Astellas Pharmaceuticals 16.4.6. Bayer Ag 16.4.7. Bio Vision 16.4.8. Celgene Corp. 16.4.9. Abcam plc 16.4.10. Thermo Fisher Scientific Inc. 16.4.11. Zymo Research Corporation 16.4.12. Eisai